By otakuyassine3@gmail.com 
Prelude Therapeutics Incorporated (NASDAQ:PRLD – Get Free Report) CEO Krishna Vaddi acquired 100,000 shares of Prelude Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The stock was bought at an average price of $0.93 per share, with a total value of $93,000.00. Following the purchase, the chief executive officer now directly owns 1,167,275 shares of the company’s stock, valued at approximately $1,085,565.75. This trade represents a 9.37 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
Prelude Therapeutics Price Performance
PRLD traded up $0.32 during midday trading on Friday, reaching $1.21. 2,843,192 shares of the company’s stock were exchanged, compared to its average volume of 198,793. Prelude Therapeutics Incorporated has a 1-year low of $0.80 and a 1-year high of $6.80. The stock has a market capitalization of $66.32 million, a PE ratio of -0.68 and a beta of 1.49. The business’s 50-day moving average price is $1.22 and its 200 day moving average price is $3.19.
Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.05. The company had revenue of $3.00 million for the quarter. As a group, analysts expect that Prelude Therapeutics Incorporated will post -1.81 EPS for the current fiscal year.
Institutional Trading of Prelude Therapeutics
A number of large investors have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. boosted its stake in shares of Prelude Therapeutics by 885.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 174,979 shares of the company’s stock worth $362,000 after purchasing an additional 157,218 shares during the last quarter. State Street Corp lifted its stake in shares of Prelude Therapeutics by 35.1% during the third quarter. State Street Corp now owns 286,046 shares of the company’s stock valued at $592,000 after buying an additional 74,300 shares during the period. Walleye Capital LLC boosted its position in Prelude Therapeutics by 446.2% during the third quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock worth $172,000 after acquiring an additional 67,946 shares during the last quarter. XTX Topco Ltd purchased a new stake in Prelude Therapeutics in the 3rd quarter worth approximately $100,000. Finally, Geode Capital Management LLC raised its holdings in Prelude Therapeutics by 8.2% in the 3rd quarter. Geode Capital Management LLC now owns 391,716 shares of the company’s stock valued at $811,000 after acquiring an additional 29,765 shares during the last quarter. Institutional investors and hedge funds own 79.72% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on PRLD shares. JMP Securities reiterated a “market outperform” rating and set a $4.00 price target (down from $7.00) on shares of Prelude Therapeutics in a research report on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Prelude Therapeutics in a report on Friday, November 8th.
Check Out Our Latest Stock Analysis on Prelude Therapeutics
About Prelude Therapeutics
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.
See Also
Receive News & Ratings for Prelude Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Prelude Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.